Browsing by Subject "Eye"
Now showing 1 - 8 of 8
- Results Per Page
- Sort Options
Item Immune-Mediated Mechanisms of Phthisical and Non-Phthisical Intraocular Tumor Rejection(2011-12-12) Coursey, Terry Glenn, II; Niederkorn, Jerry Y.Although intraocular tumors reside in an immunoprivileged site where immune responses are suppressed, some tumors are rejected nonetheless. An example of this is the syngeneic adenovirus-induced (Ad5E1) tumor model. Intraocular tumors are rejected in one of two pathways: one that maintains normal architecture and function of the eye and one that causes gross destruction leading to necrosis or phthisis. Ad5E1 tumor cell lines were created from single cell clones that are consistently rejected in a phthisical manner or non-phthisical manner. The first objective sought to characterize non-phthisical intraocular tumor rejection. I demonstrated that this form of rejection is dependent on T cells. Rejection was also found to be dependent on M1 macrophages that mediate cytotoxicity; however, iNOS was not required. An unidentified soluble factor was determined to be responsible for macrophage-mediated killing. My results indicated that T cells and M1 macrophages were required for phthisical rejection of intraocular Ad5E1 clone 2.1. In addition, in vitro inhibition of iNOS abolished most of the macrophage-mediated killing of the tumor cells, and in vivo results indicated that iNOS was essential for controlling the growth of the intraocular tumors. Studies in tumor necrosis factor (TNF)-deficient mice revealed that although TNF-alpha was not necessary for tumor rejection, it was required for phthisis. Thus, this model demonstrates that it is possible to modify the host’s response such that the immune system eliminates the intraocular tumor while preserving the integrity of the eye. The last aim sought to determine the mechanisms of IFN-gamma-independent tumor rejection. Although phthisically-rejected Ad5E1 tumors were not rejected when transplanted into the eyes of IFN-gamma KO mice, they were rejected following subcutaneous transplantation (SC). Thus, outside of the eye, Ad5E1 tumors elicit a form of tumor immunity that is IFN-gamma-independent. SC tumor rejection required IL-17, which was produced by CD4+ T cells in response to tumor antigens (TAs). Additionally, depletion of IL-17 decreased CTL activity against Ad5E1 tumor cells. However, this does not occur in the eye. IL-6 production within the eye is severely reduced, which is consistent with the failure to induce Th17 cells within the intraocular tumors. Therefore, IFN-gamma-independent tumor rejection is excluded from the eye and may represent a newly recognized form of ocular immune privilege.Item Mechanisms of p19Arf-Mediated Regulation of Perivascular Cell Biology During Mammalian Eye Development(2015-08-03) Iqbal, Nida S.; Johnson, Jane E.; Mendell, Joshua T.; Gupta, Rana K.Since its discovery in 1995, p19Arf has been under critical interrogation for its role as a potent cell cycle regulator and tumor suppressor. In the last decade, there has been considerable evidence describing an essential function for p19Arf during mammalian eye development. In this context, p19Arf is required for the ultimate involution of the hyaloid vasculature system that exists in the primary vitreous space and serves to nourish the lens and retina. Knock-out mouse models for p19Arf demonstrate that in the absence of Arf, there is an abnormal accumulation of cells that persist into the adult secondary vitreous and cause detrimental ocular defects including blindness, retinal detachment and lens opacity. It has been further demonstrated that p19Arf enacts a dual mechanism to inhibit the accumulation of the perivascular cells that occupy the vitreous space during development and lead to the clearing of these cells followed by eventual involution of the underlying vasculature system. Platelet-derived growth factor receptor β (Pdgfrβ) is required for the accumulation of cells in the absence of Arf and while it is clear that p19Arf utilizes a p53-dependent mechanism to inhibit Pdgfrβ transcription, the mechanism by which it can inhibit Pdgfrβ protein in the absence of p53 is not well defined. Further, the biological consequences of Arf expression have, to date, only been studied in a context in which Arf is not normally expressed, such as during tumor progression and culture shock. This work addresses these two open questions. First, I will discuss a novel capacity for p19Arf to employ microRNAs outside of the p53 pathway to lead to repression of Pdgfrβ protein. Next I will describe an ex vivo cell culture system to study unexplored facets of Arf biology in a context in which it is endogenously expressed.Item [News](1987-11-10) Bosler, Tommy JoyItem The silk road: Behcet's disease and its fellow travelers(2022-09-23) Kazi, SalahuddinItem [Southwestern News](1995-09-18) Abila, ReyesItem [Southwestern News](2005-05-20) Maier, ScottItem [UT News](1987-10-09) Adell, DianeItem [UT Southwestern Medical Center News](2008-03-20) McKenzie, Aline